Upgrade to SI Premium - Free Trial

Guggenheim Reiterates Buy Rating on Merck (MRK)

August 20, 2026 6:47 AM
Guggenheim analyst Vamil Divan reiterated a Buy rating and $146.00 price target on Merck (NYSE: MRK).The analyst commented: "MRK and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments